New Treatment Options for Prostate Cancer
|
|
- Doreen Warner
- 5 years ago
- Views:
Transcription
1 New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer Institute Richard Heyman, CEO, Seragon (ex-ceo Aragon) Marco Gottardis, PhD, VP and Prostate Cancer Disease Area Stronghold Leader, Oncology Therapeutic Area, Janssen Research & Development, LLC Brian Richard Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company Marianne Sadar, PhD, Distinguished Scientist, BC Cancer Agency. Professor of Pathology and Laboratory Medicine, University of British Columbia 1
2 New Treatment Options for Prostate Cancer Richard Gaynor, M.D. Sr. Vice President Oncology Clinical Development and Medical Affairs Lilly Oncology 2
3 Drug Development in Prostate Cancer Genetic Changes Pathway inhibitors Immunotherapeutic approaches Clinical status
4 Clinically Relevant Genomic Alterations in Prostate Cancer Gene Alteration Type Frequency (%) Potential Treatment Hypotheses ETS transcription factors Rearrangement 50 Indirect targeting of ETS gene fusions through PARP or DNAPK inhibitors Androgen receptor Mutation Amplification PTEN Loss 50 PI3K pathway inhibitors J Clin Oncol 31: by American Society of Clinical Oncology Androgen synthesis inhibitors, next-generation androgen receptor antagonists RB1 Loss 25 to 60 Role in disease progression and castrate resistance with potential for targeting PIK3CA Amplification Mutation MYC Amplification PI3K pathway inhibitors Potential for targeting Neuroendocrine prostate cancer AURKA Amplification 5 Aurora kinase inhibitors, co-occurs with MYC in 40% of neuroendocrine prostate cancers AKT Mutation 1 to 2 AKT inhibitors RAF KRAS Rearrangement Mutation Mutation Rearrangement 1 to 2 RAF inhibitors 1 RAF, MEK, or PI3K inhibitors NOTE: Summarizes alterations in prostate cancer that have a treatment hypothesis currently being explored preclinically or in clinical trials. The most common alterations with a treatment hypothesis involve ETS rearrangements, androgen receptor, and PTEN loss. With only a limited number of samples assessed, a majority of these alterations are not necessarily mutually exclusive. Abbreviation: PI3K, phosphatidylinositide 3-kinase.
5 Pathway-guided Treatment in Prostate Cancer J Clin Oncol 31: by American Society of Clinical Oncology
6 Translating Genomics for Prostate Cancer Trials J Clin Oncol 31: by American Society of Clinical Oncology
7 The Changing Treatment Landscape of Prostate Cancer Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School March 4 5, 2014 Conrad New York
8 Prostate Cancer: The Old Treatment Paradigm Therapies after LHRH agonists anti-androgens etc. Post Chemo A Hormone Sensitive B C Castration Resistant CRPC
9 The Treatment Landscape in 2014 Standard Androgen Deprivation Therapy Denosumab, Zoledronic Acid Radium-223 Enzalutamide Local Therapy Androgen Deprivation Therapies After LHRH Agonists and Antiandrogens Abiraterone Chemotherapy Death Postchemotherapy Sipuleucel-T Docetaxel Cabazitaxel
10 Immunotherapy AR-Targeting Therapies Chemotherapy Bone Targeted Agents
11 ANDROGEN SIGNALING BLOCKERS 11
12 Androgen Dependent Cell CRPC
13 mhspc-lower PSA Nadir: Better Outcome With ADT (Proportion of CRPC Cells in Population?) Hussain M, et al. J Clin Oncol, 2006
14 Mechanisms of Resistance To Primary Androgen Deprivation Therapy Adaptive mechanisms by which hormone sensitive cells reprogram in response to ADT Androgen receptor mediated mechanisms Ligand and AR independent mechanisms Alternative molecular signaling pathways Clonal selection (ex: neuroendocrine differentiation) Ligand dependency despite low ligand availability
15 Examples of AR Mediated Mechanisms AR mutations and amplification AR reprogramming
16 Androgen Receptor Reprogramming Wang Q, et al. Cell. 2009;138(2):
17 Ligand and AR independent Mechanisms Clinical Observations Alternative molecular signaling pathways Largely not known Evolution of AR and PSA negative cells Acquisition of neuroendocrine differentiation
18 Importance of Persistent Ligand in CRPC Genetic evidence-ar-mutated or amplified AR (Taplin and others) Probably low frequency events Persistent AR expression and expression of androgen regulated genes androgen signature (Chen et al, Stanbrough et al) including genes involved in conversion of precursors to T and DHT (Balk et al and Nelson et al) Persistent intratumoral ligand -T or DHT or precursors Intratumoral conversion Persistent androgen in CRPC tissue (Geller, Mohler, Montgomery, Nelson)
19 FDA Approved Androgen Signaling Pathway Inhibitors CYP 17, 20 lyase inhibitors-androgen biosynthesis inhibitors Abiraterone acetate Antiandrogens-block AR action Enzalutamide (MDV3100)
20 Abiraterone in mcrpc Pre- and Post-Chemotherapy* mcrpc Pre-chemotherapy mcrpc 1 st Line Chemotherapy mcrpc Post-chemotherapy COU-AA-302 Co-Primary Endpoints: OS, rpfs COU-AA-301 Primary Endpoint: OS *FDA approved indications
21 Enzalutamide in mcrpc Pre- and Post-Chemotherapy mcrpc Pre-chemotherapy mcrpc 1 st Line Chemotherapy mcrpc Post-chemotherapy PREVAIL Co-Primary Endpoints: OS and rpfs AFFIRM Primary Endpoint: OS
22 Conclusions Understanding the persistence of the androgen signaling pathway in CRPC has been transformative Multiple agents with varied mechanisms extend survival and delay progression Cross resistance occurs between agents Active agents against similar targets (eg. Orterenol) have failed to meet endpoint
23 Questions What is the optimal sequencing and/or combination of agents? Can we develop predictive biomarkers of efficacy? Can we cure patients by using these drugs earlier in the treatment paradigm (adjuvantly)? How much further can we get by extinguishing the AR pathway completely?
24 IMMUNOTHERAPY 24
25 Sipuleucel-T (Provenge)
26 Sipuleucel-T: Presumed Mechanism of Action Antigen (PAP- GMCSF) is exposed to an Antigen Presenting Cell (APC) APC takes up the antigen Antigen is processed and presented on surface of the APC Fully activated, the APC is now sipuleucel-t and is collected INFUSE PATIENT T-cells proliferate and attack cancer cells sipuleucel-t activates T-cells in the body
27 Vaccines-Questions While this was a breakthrough in terms of validating a new MOA and validating the principles of immunotherapy, the acceptance and adoption has been very slow: Cumbersome administration Controversial MOA-does it really work the way we thought? Few PSA declines No measurable prolongation in TTP (NB-time to first progression) Other agents with more straightforward MOAs have been developed Cost and initially uncertainty of reimbursement
28 Will Vaccines Survive? Challenges Takes a long time to have a clinical effect Adjuvant treatments (chemotherapy/hormonal therapy in breast and colon CA) are similar but easier to understand Antiresorptive agents-tangible clinical readout although very modest The Future Vaccine development may develop more robust effects in short term-unlikely in short term in light of MOA Need more efficient production procedures Combining with other agents seems better approach Active hormonal agents or chemotherapy Checkpoint inhibitors Vaccines will have a role in the future 28
29 Immunotherapy-Looking ahead What will the role of checkpoint blockade be? Ipilimumab PD-1, PDL-1 Will CAR-T cells emerge as a viable therapy? 29
30 BONE TARGETING-RADIUM
31 Radium-223 Targets Bone Metastases Radium-223 acts as a calcium mimic Naturally targets new bone growth in and around bone metastases Radium-223 is excreted by the small intestine Ca Sr Ba Ra
32 Radium-223 Targets Bone Metastases Range of alpha-particle Radium-223 Bone surface Alpha-particles induce double-strand DNA breaks in adjacent tumour cells 1 Short penetration of alpha emitters (2-10 cell diameters) = highly localized tumour cell killing and minimal damage to surrounding normal tissue Perez Conrad et NY, al. Principles March 4 and 5, 2014 Practice of Radiation Oncology. 5th ed. Lippincott Williams & Wilkins; 2007:103.
33 ALSYMPCA Phase III Study Design PATIENTS Confirmed symptomatic CRPC 2 bone metastases No known visceral metastases or >3 cm nodes Post-docetaxel or unfit for docetaxel or refusing docetaxel STRATIFICATION Total ALP: < 220 U/L vs 220 Bisphosphonates: Yes vs No Prior docetaxel: Yes vs No R A N D O M I Z E D 2:1 N = 922 TREATMENT 6 injections at 4-week intervals Radium-223 (50 kbq/kg) + Best standard of care Placebo (saline) + Best standard of care
34 Radium 223-Conclusions Radium-223: Significantly prolonged median OS Significantly prolonged median time to first SRE by 5.5 months Benefit to pre and post chemotherapy patients
35 Radium-223: Radium 223-Questions Rare declines in PSA Given over 6 months Optimal timing Can it be used earlier successfully and safely Can it be successfully combines with other agents
36 The Future-Targets How far will precision medicine get us in prostate cancer? What are other viable targets and can they successfully be drugged? 36
37 The Future-Endpoints What endpoints will be acceptable in the future? OS benefit will become harder to achieve because of multiple approved drugs and will take longer to read out What is the meaning of PFS in prostate cancer? Some agents prolong PFS and not OS and vice versa What is the meaning of MFS in prostate cancer? Does this translate into clinical benefit to the patient? 37
38 Phase III Study of ARN-509 in Men With Non-Metastatic CRPC (SPARTAN) Patients with non-metastatic CRPC with high-risk disease Enrollment Goal N = 1200 R A N D O M I Z E D 2:1 ARN mg daily Placebo Daily Endpoints Primary: Metastasisfree survival Key Secondary: OS rpfs Time to chemo
39 The Future-Endpoints What endpoints will be acceptable in the future? OS benefit will become harder to achieve because of multiple approved drugs and take longer to read out What is the meaning of PFS in prostate cancer? Some agents prolong PFS and not OS and vice versa What is the meaning of MFS in prostate cancer? Does this translate into clinical benefit to the patient? What meaningful intermediate endpoints that translate into clinical benefit can we develop? CURE SHOULD BE OUR GOAL 39
Philip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationProstate Cancer: Vision of the Future By: H.R.Jalalian
1 H. R. Jalalian Hematologist&Oncologist Baqiyatallah University of Medical Sciences 2 State of the art: vision on the future Diagnosis Surgery Radiotherapy Medical Oncology 3 Early Detection PSA sensitivity
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationAndrogens and prostate cancer: insights from abiraterone acetate and other novel agents
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationImmunotherapy of Prostate Cancer
Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationAdvanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationSummary... 2 GENITOURINARY TUMOURS - PROSTATE... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 Custirsen provides no additional survival benefit to cabazitaxel/prednisone
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationRoberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
Il Trattamento della Malattia CRPC metastatica Terapie Radiometaboliche Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena AIOM: Gestione ottimale del Paziente con Carcinoma della
More informationThe Current Prostate Cancer Landscape
A Phase 1-2 Dose-Escalation and Safety Study of ADXS-PSA Alone and of ADXS-PSA in Combination with KEYTRUDA (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationINTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER
INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationProstate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy).
Thanks to: The Medical Educator Consortium Luis Raez, MD, Florida International University 15th ed. Prostate Cancer Management: From Early Chemical Recurrence to HRPC (excluding Immunotherapy). Mayer Fishman,
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationRationale Design of Combination Therapy in Prostate Cancer: Targeting the AR and PI3K pathways
Rationale Design of Combination Therapy in Prostate Cancer: Targeting the AR and PI3K pathways Brett S Carver, MD Assistant Attending, Department of Surgery/Urology Prostate Cancer Therapeutics: A Changed
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationCastrate resistant prostate cancer: the future of anti-androgens.
Castrate resistant prostate cancer: the future of anti-androgens. Dmitri Pchejetski 1,2*, Heba Alshaker 3, Justin Stebbing 3,4* 1. Department of Medicine, Imperial College, London, UK 2. School of Medicine,
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationEvolution or revolution in the treatment of prostate cancer
Evolution or revolution in the treatment of prostate cancer de Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Professor of Experimental Cancer Medicine Department of Medicine/ Drug Development Unit
More informationA Forward Look at Options for. In Prostate Cancer
A Forward Look at Options for Prostate Cancer Charles J Ryan, MD Associate Professor of Medicine Helen Diller Family Comprehensive Cancer Center University of California, San Francisco UC 1 SF UC SF Castration
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationAnti-Androgen Therapies for Prostate Cancer: A Focused Review
Anti-Androgen Therapies for Prostate Cancer: A Focused Review Nischala Ammannagari, MD, and Saby George, MD, FACP Abstract Among men in the United States, prostate cancer is the most common malignancy
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationProgress in Metastatic Prostate Cancer
Integrating Current & Novel Treatment Strategies for the Management of CRPC Charles J Ryan, MD Thomas Perkins Distinguished Professor of Medicine and Urology Helen Diller Family Comprehensive Cancer Center
More informationRadiopharmaceuticals for treating CRPC patients with metastatic bone disease 2014/6/27
Radiopharmaceuticals for treating CRPC patients with metastatic bone disease 和信醫院黃玉儀 2014/6/27 Bone metastases in prostate cancer The most common site of metastasis in prostate cancer In >90% patients
More informationSOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc
SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc Stéphane OUDARD, MD, PhD Head of the Oncology department Georges Pompidou Hospital, Paris France University Rene Descartes, Paris
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationMichiel H.F. Poorthuis*, Robin W.M. Vernooij*, R. Jeroen A. van Moorselaar and Theo M. de Reijke
First-line non-cytotoxic therapy in chemotherapynaive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials Michiel H.F. Poorthuis*, Robin
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationNovel MOAs and targets for cancer drug development What s hot off the presses?
Novel MOAs and targets for cancer drug development What s hot off the presses? Moderator: Jeremy Goldberg, President, JPG Healthcare LLC Panelists: Robert J Schneider, PhD, Associate Director, NYU Cancer
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationRadium-223 (Alpharadin)
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer OLIVER SARTOR, M.D. North American Principal Investigator, ALSYMPCA trial Laborde Professor
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationNAVIGATING THE mcrpc LANDSCAPE: EXPLORING KEY CLINICAL DECISION POINTS
NAVIGATING THE mcrpc LANDSCAPE: EXPLORING KEY CLINICAL DECISION POINTS Summary of presentations from the Bayer-supported satellite symposium, held at the European Association of Urology (EAU) Congress,
More informationBoard Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending
Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant
More informationA SPECIAL MEETING REVIEW EDITION. Special Reporting on: PLUS Meeting Abstract Summaries. With Expert Commentary by:
August 2013 Volume 11, Issue 8, Supplement 11 A SPECIAL MEETING REVIEW EDITION Highlights in Advanced Prostate Cancer From the 2013 American Urological Association Annual Meeting and the 2013 American
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationRationale for Multimodality Therapy for High Risk Localized Prostate Cancer
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationNavigating Prostate Cancer Therapy. Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
Navigating Prostate Cancer Therapy Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA Disclosures In compliance with accreditation, we require the following disclosures to the
More informationOngoing trials that might change the standard of care in mcrpc
Ongoing trials that might change the standard of care in mcrpc Igor Tsaur University Medicine Mainz COI Off-label use of drugs, devices, or other agents: none Data from IRB-approved human research is presented:
More informationThe Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist
The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy
More informationUPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More information- La Terapia Farmacologica -
XXV Congresso Nazionale AIRO Simposio AIRO-AIMN: Trattamento delle Metastasi Ossee nel Paziente con Tumore della Prostata "Ormonorefrattario": - La Terapia Farmacologica - Sergio Bracarda, Medical Oncology
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationSequencing treatment for metastatic prostate cancer
11 Sequencing treatment for metastatic prostate cancer SOPHIE MERRICK, STYLIANI GERMANOU, ROGER KIRBY AND SIMON CHOWDHURY In the past 10 years there have been significant advances in the understanding
More informationPI3K/mTOR Dual Inhibitor
PI3K/mTOR Dual Inhibitor LY3023414 Courtney KD, et al 1 Drug Discovery Platform: Cancer Cell Signaling A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the
More informationAmerican Urological Association (AUA) Guideline
1 Approved by the AUA Board of Directors April 2014 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2014 by the American Urological
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationImmunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Immunotherapy and new agents in CRPC Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Clovis,
More information